You do not have the latest flash plugin or you have disabled javascript.

Posted in Pharmaceuticals Blog

FDA schedules another review of Trasylol for September 12

August 23rd, 2007 by Todd Hageman

Last September, the Food and Drug Administration reviewed Trasylol. After that, it got interesting. 

Bayer, the company the makes Trasylol, disclosed that two employees withheld information about the side effects.  Pharmalot reports that last week, Bayer insisted that the cover-up wasn’t really a cover-up.  Now, the FDA is going to revisit the issue.

As I explained in a previous blog entry, Trasylol is a drug given intravenously to prevent blood loss during heart bypass surgery.  The drug was approved in 1993 for use only on high-risk patients.  In 1998, the FDA approved its use on all patients.  Because doctors did not have to ask the patient’s permission to give the drug, few knew they received it.  It has now been linked to a much higher risk of heart attacks, strokes, and renal failure.

If you or someone you know has been injured as a result of a dangerous medication, contact Todd Hageman toll free at 1-877-767-3108.

Share This

 

Simon Passanante is nationally recognized as a result of its successful handling of jury trials on a wide variety of cases. You are invited to view the firm’s notable verdicts and settlements. Much of the information on this site is presented through videos. Other pages of this site concern Simon Passanante’s honors and awards, testimonials from clients and referring attorneys, and safety information. Our employee directory is here. If you have any questions for us, email us. See this page for important legal disclosures and to learn about contingent fees. For updates regarding Simon Passanante, we invite you to explore our law blogs.

Simon Passanante PC

701 Market Street

Suite 1450

St. Louis, Missouri 63101

314.241.2929

Toll Free: 877.767.3108

Close
E-mail It